崇達技術(002815.SZ):控股子公司普諾威專注於BT載板產品的研發生產
格隆匯7月11日丨崇達技術(002815.SZ)在互動平臺表示,控股子公司普諾威專注於BT載板產品的研發生產,在深耕MEMS類載板市場的基礎上,依靠多年累積的客戶資源和產品經驗,完成傳統封裝基板向先進封裝基板的轉型,投資4億元新建了m-SAP製程生產線,主要聚焦於RF射頻類封裝基板、SIP封裝基板、電源管理封裝基板、光通訊封裝基板等細分領域市場,目前其生產能力已提升到滿足線寬間距25/25微米IC載板主流市場水平的需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.